CUG-BP1/2 Antibody (B-1): sc-166095
- CUG-BP1/2 Antibody (B-1) is a mouse monoclonal IgG2a κ CUG-BP1/2 antibody, cited in 2 publications, provided at 200 µg/ml
- raised against amino acids 9-194 mapping near the N-terminus of CUG-BP1 of human origin
- CUG-BP1/2 Antibody (B-1) is recommended for detection of CUG-BP1 and CUG-BP2 of mouse, rat and human origin by WB, IP, IF and ELISA
- Anti-CUG-BP1/2 Antibody (B-1) is available conjugated to agarose for IP; HRP for WB, IHC(P) and ELISA; and to either phycoerythrin or FITC for IF, IHC(P) and FCM
- also available conjugated to Alexa Fluor® 488, Alexa Fluor® 546, Alexa Fluor® 594 or Alexa Fluor® 647 for WB (RGB), IF, IHC(P) and FCM, and for use with RGB fluorescent imaging systems, such as iBright™ FL1000, FluorChem™, Typhoon, Azure and other comparable systems
- also available conjugated to Alexa Fluor® 680 or Alexa Fluor® 790 for WB (NIR), IF and FCM; for use with Near-Infrared (NIR) detection systems, such as LI-COR®Odyssey®, iBright™ FL1000, FluorChem™, Typhoon, Azure and other comparable systems
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for CUG-BP1/2 Antibody (B-1). This work is in progress.
CUG-BP1/2 Antibody (B-1) is a mouse monoclonal IgG2a kappa light chain antibody that detects CUG-BP1/2 of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Anti-CUG-BP1/2 antibody (B-1) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. CUG-BP1/2 proteins play a crucial role in RNA metabolism regulation, particularly in myotonic dystrophy, a genetic disorder characterized by a (CTG)n repeat expansion in the myotonin protein kinase gene (DMPK). CUG-BP1/2 proteins bind specifically to (CUG)8 oligonucleotides, with CUG-BP1 showing predominant binding activity in normal cells, while CUG-BP2′s binding activity increases during myotonic dystrophy. CUG-BP1′s ability to regulate splicing and translation of various RNAs maintains normal cellular function by influencing translation of key proteins such as p21, essential for cell cycle regulation. In normal cells, CUG-BP1 enhances p21 translation by binding to a GC-rich sequence in the 5′ region of p21 mRNA, promoting differentiation. In myotonic dystrophy cells, reduced CUG-BP1 accumulation leads to decreased p21 levels and disrupts the balance of proteins involved in cell cycle withdrawal, highlighting CUG-BP1/2′s importance in cellular homeostasis and disease pathology.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CUG-BP1/2 Antibody (B-1) References:
- Isolation and expression of Napor/CUG-BP2 in embryo development. | Choi, DK., et al. 2003. Biochem Biophys Res Commun. 305: 448-54. PMID: 12763013
- Transgenic mice expressing CUG-BP1 reproduce splicing mis-regulation observed in myotonic dystrophy. | Ho, TH., et al. 2005. Hum Mol Genet. 14: 1539-47. PMID: 15843400
- CUG-BP1/CELF1 requires UGU-rich sequences for high-affinity binding. | Marquis, J., et al. 2006. Biochem J. 400: 291-301. PMID: 16938098
- Interaction of muscleblind, CUG-BP1 and hnRNP H proteins in DM1-associated aberrant IR splicing. | Paul, S., et al. 2006. EMBO J. 25: 4271-83. PMID: 16946708
- Quantitative analysis of CUG-BP1 binding to RNA repeats. | Mori, D., et al. 2008. J Biochem. 143: 377-83. PMID: 18039683
- Structural basis for the sequence-specific RNA-recognition mechanism of human CUG-BP1 RRM3. | Tsuda, K., et al. 2009. Nucleic Acids Res. 37: 5151-66. PMID: 19553194
- The RNA-binding protein CUG-BP1 increases survivin expression in oesophageal cancer cells through enhanced mRNA stability. | Chang, ET., et al. 2012. Biochem J. 446: 113-23. PMID: 22646166
- Overexpression of miR-214-3p in esophageal squamous cancer cells enhances sensitivity to cisplatin by targeting survivin directly and indirectly through CUG-BP1. | Phatak, P., et al. 2016. Oncogene. 35: 2087-97. PMID: 26234674
- CUG-BP1 regulates RyR1 ASI alternative splicing in skeletal muscle atrophy. | Tang, Y., et al. 2015. Sci Rep. 5: 16083. PMID: 26531141
- Resveratrol corrects aberrant splicing of RYR1 pre-mRNA and Ca2+ signal in myotonic dystrophy type 1 myotubes. | Santoro, M., et al. 2020. Neural Regen Res. 15: 1757-1766. PMID: 32209783
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CUG-BP1/2 Antibody (B-1) | sc-166095 | 200 µg/ml | $316.00 | |||
CUG-BP1/2 Antibody (B-1) AC | sc-166095 AC | 500 µg/ml, 25% agarose | $416.00 | |||
CUG-BP1/2 Antibody (B-1) HRP | sc-166095 HRP | 200 µg/ml | $316.00 | |||
CUG-BP1/2 Antibody (B-1) FITC | sc-166095 FITC | 200 µg/ml | $330.00 | |||
CUG-BP1/2 Antibody (B-1) PE | sc-166095 PE | 200 µg/ml | $343.00 | |||
CUG-BP1/2 Antibody (B-1) Alexa Fluor® 488 | sc-166095 AF488 | 200 µg/ml | $357.00 | |||
CUG-BP1/2 Antibody (B-1) Alexa Fluor® 546 | sc-166095 AF546 | 200 µg/ml | $357.00 | |||
CUG-BP1/2 Antibody (B-1) Alexa Fluor® 594 | sc-166095 AF594 | 200 µg/ml | $357.00 | |||
CUG-BP1/2 Antibody (B-1) Alexa Fluor® 647 | sc-166095 AF647 | 200 µg/ml | $357.00 | |||
CUG-BP1/2 Antibody (B-1) Alexa Fluor® 680 | sc-166095 AF680 | 200 µg/ml | $357.00 | |||
CUG-BP1/2 Antibody (B-1) Alexa Fluor® 790 | sc-166095 AF790 | 200 µg/ml | $357.00 |